Categories: News

Embolx Launches Sniper G3: Revolutionizing Embolization with Enhanced Efficiency, Ease of Use, and Extended Shelf Life

SUNNYVALE, Calif., July 28, 2025 /PRNewswire/ — Embolx, a leader in advanced microcatheters for targeted embolization procedures, today announced the release of its next-generation Sniper G3 Balloon Occlusion Microcatheter. This third iteration of the innovative device delivers significant enhancements, including an extended shelf life, improved ease of use, and streamlined preparation, directly addressing critical feedback from physician users.

- Advertisement -

The highly anticipated Sniper G3 features a 24-month shelf life, doubling the longevity of its predecessor. This improvement offers greater inventory flexibility for hospitals and clinics. Designed with direct input from interventional radiologists, Sniper G3 also features improved trackability and a simplified preparation process, significantly reducing pre-procedure setup time. The new prep method eliminates several steps, cutting preparation time down to less than a minute, a crucial gain in fast-paced clinical environments. This focus on user feedback underscores Embolx’s commitment to developing intuitive, high-performance tools that enhance clinical workflow.

- Advertisement -

Sniper G3 truly exemplifies our dedication to innovation driven by physician needs,” said Michael Allen, President and CEO of Embolx. “We listened intently to our users and engineered a device that not only extends product longevity and improves performance, but also significantly enhances the ease of use, which translates directly to more efficient procedures. We are incredibly proud of Sniper G3 and its potential to set a new standard in embolization therapy.”

- Advertisement -

The Sniper G3 Balloon Occlusion Microcatheter represents a significant leap forward in Embolx’s commitment to physician-centric innovation. It is available in all standard lengths and is ready for worldwide distribution.

- Advertisement -

About Embolx
Embolx has pioneered advanced pressure-mediated delivery of therapeutics directly into cancerous tumors, prostates, and other anatomical structures and is dedicated to transforming healthcare through the development of innovative technologies.

- Advertisement -

For media inquiries, please contact:

- Advertisement -

Haley McGregor
Global Marketing and Sales Operations Manager
hmcgregor@embolx.com

- Advertisement -

Logo – https://mma.prnewswire.com/media/2738641/Sniper_g3_Logo.jpg 

- Advertisement -

View original content:https://www.prnewswire.co.uk/news-releases/embolx-launches-sniper-g3-revolutionizing-embolization-with-enhanced-efficiency-ease-of-use-and-extended-shelf-life-302514310.html

- Advertisement -

Recent Posts

Hyundai Motor Group Showcases Hydrogen Technologies Across the Value Chain at World Hydrogen Expo in Korea

Hyundai Motor Group, together with its 7 affiliates, highlights cutting-edge hydrogen technologies and real-world applications…

9 minutes ago

Spectacular celebrations as the Olympic flame arrives in Italy ahead of the Olympic Winter Games Milano Cortina 2026

05 December 2025 - Celebrations have taken place in Rome to mark the arrival of the…

10 minutes ago

14th Olympic Summit on 11 December 2025 Information for the media

05 December 2025 - The International Olympic Committee (IOC) will host the 14th Olympic Summit on…

10 minutes ago

CocaCola music festival set to ignite Olympic Torch Relay celebrations in Rome

05 December 2025 - As the Olympic flame prepares to begin its journey through Italy ahead…

10 minutes ago

Godrej Industries Group’s Assistive Tech Conference promotes accessible and equitable workplaces in India

MUMBAI, India, Dec. 6, 2025 /PRNewswire/ -- Godrej Industries Group recently hosted its inaugural Assistive…

1 hour ago

Toripalimab Presents Long-Term Survival Benefits as 1st-line Treatment for Advanced Nasopharyngeal Carcinoma and Esophageal Squamous Cell Carcinoma Patients

Long-term OS follow-up analysis of JUPITER-02 demonstrates significantly better and clinically meaningful improvement with toripalimab…

3 hours ago